Business Context and Reporting Period
Filing inconsistency: The request identifies Palisade Bio, Inc., but the provided Form 10-Q is for Neuralstem, Inc., for the quarter ended September 30, 2015. The summary below reflects the provided filing.
Neuralstem is a development-stage regenerative medicine company focused on human neural stem-cell therapies and small-molecule compounds. Its principal programs include NSI-566 for ALS, spinal cord injury and stroke, and NSI-189 for major depressive disorder and cognitive deficits in schizophrenia. No proposed therapy had been approved for commercial sale.
As of October 31, 2015, 91,786,290 common shares were outstanding. The company began trading on the NASDAQ Capital Market under the symbol “CUR” in July 2015.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $2,500 in 2015 versus $5,000 in 2014 | $7,917 in 2015 versus $14,167 in 2014 |
| Operating expenses | $5.2 million versus $4.1 million | $14.8 million versus $12.8 million |
| Operating loss | $5.2 million versus $4.1 million | $14.8 million versus $12.8 million |
| Net loss | $5.6 million versus $4.5 million | $16.1 million versus $17.1 million |
| Net loss per share | $0.06 versus $0.05 | $0.18 versus $0.20 |
| Operating cash flow | Not separately provided | $(15.0) million versus $(8.2) million |
Research and development expense was $9.9 million for the first nine months, up 72%, primarily due to increased project, laboratory, payroll, stock compensation and rent costs associated with expanded clinical and preclinical efforts. General and administrative expense declined 30% to $4.9 million, mainly because of lower stock-based compensation and legal expenses.
The filing does not present a meaningful operating margin because revenue was nominal relative to operating expenses. The nine-month net loss was approximately $16.1 million, with no revenue from product sales.
Liquidity, Debt and Capital Resources
- Cash and cash equivalents were $13.1 million at September 30, 2015, compared with $12.5 million at December 31, 2014.
- Short-term investments were $5.0 million, down from $15.0 million; total cash, cash equivalents and short-term investments were approximately $18.1 million versus $27.5 million at year-end 2014.
- Working capital surplus was approximately $12.1 million, and stockholders’ equity was $8.9 million.
- Aggregate long-term secured debt was approximately $9.5 million. The debt was secured by substantially all assets, including intellectual property, and carried a variable interest rate with a 10% floor.
- Monthly principal and interest payments of approximately $461,000 were scheduled from October 2015 through March 2017, followed by an approximately $2.1 million balloon payment in April 2017.
- Financing activities generated $5.8 million during the first nine months, including $3.1 million from warrant exercises and $2.9 million from at-the-market equity sales.
- The company stated that it would require significant additional capital to continue development, clinical trials, manufacturing and general operations. Management did not expect profitability in the next several years.
Material Changes Versus Prior Comparable Period
- Nine-month revenue declined 44%, from $14,167 to $7,917, and remained limited to intellectual-property licensing fees.
- Nine-month research and development expense increased $4.1 million, or 72%, reflecting expanded development activity.
- Nine-month general and administrative expense decreased $2.1 million, or 30%, primarily due to lower non-cash stock compensation and litigation-related legal expenses.
- Nine-month net loss improved by $1.0 million because 2014 included $3.1 million of warrant modification expense and $334,000 of derivative fair-value losses; these items did not recur in 2015. The improvement was partly offset by higher operating costs and interest expense.
- Operating cash burn increased 83% to $15.0 million, despite the lower reported net loss.
- Investing cash flow was positive $9.8 million in 2015 versus negative $15.5 million in 2014, primarily because short-term investments purchased in 2014 matured in 2015.
- Common shares outstanding increased from 87.8 million at December 31, 2014 to 91.8 million at September 30, 2015, reflecting equity issuance and warrant exercises.
Guidance, Outlook, Risks and Unusual Items
- Management expected R&D and general and administrative expenses to increase as clinical programs expand, subject to available funding.
- The company expected to enroll the first patient in a Phase II NSI-189 major depressive disorder trial in the first quarter of 2016 and expected an NSI-189 schizophrenia Phase Ib trial to commence in 2016.
- Management expected to begin Phase II development of the ischemic stroke program in 2016 and sought FDA guidance regarding a registration-directed ALS trial.
- The final patient in the chronic spinal cord injury Phase Ib study was treated in July 2015, with a six-month observation period continuing.
- The company began bringing clinical-grade spinal cord stem-cell manufacturing in-house during 2015, while continuing to rely substantially on third-party manufacturers and research organizations.
- Key risks include the absence of approved products or commercial product revenue, continuing losses and cash burn, dependence on additional financing, debt repayment and covenant obligations, clinical-trial failure or delay, regulatory uncertainty, manufacturing and supply risks, intellectual-property challenges, third-party dependence and potential equity dilution.
- The company disclosed that prior disclosure-control deficiencies identified in the June 30, 2015 Form 10-Q had been remediated through new finance personnel, enhanced whistleblower protocols, expense and disbursement procedures, and increased Audit Committee oversight. Management concluded that disclosure controls were effective as of September 30, 2015.
- A long-running patent dispute with StemCells, Inc. was dismissed with prejudice after a July 2015 standing ruling, and the parties entered into a settlement dismissing all claims and counterclaims with prejudice on September 10, 2015.
Investor Verification Checklist
- Verify the issuer identity: the supplied filing is for Neuralstem, Inc., not Palisade Bio, Inc.
- Assess available liquidity against the approximately $15.0 million annualized operating cash burn and scheduled debt payments.
- Review the terms, covenants and collateral provisions of the secured loan, including the April 2017 balloon payment.
- Track additional equity issuance, warrant exercises and potential dilution; approximately 37.3 million shares were reserved for equity awards at September 30, 2015.
- Confirm clinical-trial enrollment, regulatory milestones and whether the projected 2016 programs proceeded as planned.
- Evaluate the effectiveness of the stated internal-control remediation in subsequent filings.
- Review the status and enforceability of the company’s patent portfolio and the terms of the StemCells settlement.